Literature DB >> 17768598

Targeting endothelial and tumor cells with semaphorins.

Diane R Bielenberg1, Michael Klagsbrun.   

Abstract

Neuropilins (NRP) are receptors for the class 3 semaphorin (SEMA3) family of axon guidance molecules and the vascular endothelial growth factor (VEGF) family of angiogenesis factors. Although the seminal studies on SEMA3s and NRPs first showed them to be mediators of axon guidance, it has become very apparent that these proteins play an important role in vascular and tumor biology as well. Neuronal guidance and angiogenesis are regulated similarly at the molecular level. For example, SEMA3s not only repel neurons and collapse axon growth cones, but have similar effects on endothelial cells and tumor cells. Preclinical studies indicate that SEMA3F is a potent inhibitor of tumor angiogenesis and metastasis. In addition, neutralizing antibodies to NRP1 enhance the effects of anti-VEGF antibodies in suppressing tumor growth in xenograft models. This article reviews NRP and SEMA3 structural interactions and their role in developmental angiogenesis, tumor angiogenesis and metastasis based on cell culture, zebrafish and murine studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17768598     DOI: 10.1007/s10555-007-9097-4

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  38 in total

Review 1.  Tumor angiogenesis.

Authors:  Robert S Kerbel
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

2.  Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F.

Authors:  Silvia Coma; Dhara N Amin; Akio Shimizu; Anna Lasorella; Antonio Iavarone; Michael Klagsbrun
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

3.  Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.

Authors:  Hon-Kit Wong; Akio Shimizu; Nathaniel D Kirkpatrick; Igor Garkavtsev; Annie W Chan; Emmanuelle di Tomaso; Michael Klagsbrun; Rakesh K Jain
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

Review 4.  The intragraft microenvironment as a central determinant of chronic rejection or local immunoregulation/tolerance.

Authors:  Johannes Wedel; Hironao Nakayama; Nora M Kochupurakkal; Josephine Koch; Michael Klagsbrun; Diane R Bielenberg; David M Briscoe
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

5.  ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells.

Authors:  Jonathan Clarhaut; Robert M Gemmill; Vincent A Potiron; Slimane Ait-Si-Ali; Jean Imbert; Harry A Drabkin; Joëlle Roche
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

6.  GIPC proteins negatively modulate Plexind1 signaling during vascular development.

Authors:  Jorge Carretero-Ortega; Zinal Chhangawala; Shane Hunt; Carlos Narvaez; Javier Menéndez-González; Carl M Gay; Tomasz Zygmunt; Xiaochun Li; Jesús Torres-Vázquez
Journal:  Elife       Date:  2019-05-03       Impact factor: 8.140

7.  ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells.

Authors:  Akio Shimizu; Akiko Mammoto; Joseph E Italiano; Elke Pravda; Andrew C Dudley; Donald E Ingber; Michael Klagsbrun
Journal:  J Biol Chem       Date:  2008-07-25       Impact factor: 5.157

8.  Metabolic stress induces the lysosomal degradation of neuropilin-1 but not neuropilin-2.

Authors:  Donggoo Bae; Shaolei Lu; Cherie A Taglienti; Arthur M Mercurio
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

Review 9.  Semaphorins and their receptors in lung cancer.

Authors:  Vincent A Potiron; Joëlle Roche; Harry A Drabkin
Journal:  Cancer Lett       Date:  2008-07-14       Impact factor: 8.679

10.  Expression of semaphorin 3A and its receptors in the human intervertebral disc: potential role in regulating neural ingrowth in the degenerate intervertebral disc.

Authors:  Sotonye K Tolofari; Stephen M Richardson; Anthony J Freemont; Judith A Hoyland
Journal:  Arthritis Res Ther       Date:  2010-01-05       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.